3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing

July 22, 2026
Posted by: Kunal Singla
Category: News

Divi’s Laboratories, Laurus Labs and domestic API manufacturers continue benefiting from India’s production-linked incentive scheme for bulk drug manufacturing.

Divi’s Laboratories, Laurus Labs and Aarti Drugs are among the PLI scheme beneficiary stocks in pharma and API manufacturing, each positioned within India’s PLI scheme pharma and API manufacturing beneficiaries growth story through distinct business drivers.

India’s PLI scheme pharma and API manufacturing beneficiaries sector continues to see sustained investment and demand growth, and PLI scheme beneficiary stocks in pharma and API manufacturing reflects companies with the clearest exposure to this trend.

Click Here – Get Free Investment Predictions

This article examines Divi’s Laboratories, Laurus Labs and Aarti Drugs as PLI scheme beneficiary stocks in pharma and API manufacturing, covering their specific growth drivers and the risks of this theme.

Table of Contents

What Defines the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing

The PLI scheme beneficiary stocks in pharma and API manufacturing are companies with direct exposure to PLI scheme pharma and API manufacturing beneficiaries, combining relevant scale with disclosed growth or expansion plans.

Understanding these PLI scheme beneficiary stocks in pharma and API manufacturing helps investors identify names positioned to benefit from sustained sector-wide demand rather than one-off catalysts.

Why These Are the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing

Divi’s Laboratories’s large-scale API manufacturer benefiting from bulk drug PLI incentives, Laurus Labs’s diversified API manufacturer benefiting from bulk drug PLI scheme incentives and Aarti Drugs’s API manufacturer benefiting from bulk drug self-reliance incentive scheme together explain why these represent the PLI scheme beneficiary stocks in pharma and API manufacturing.

Divi’s Laboratories’s large-scale API manufacturer benefiting from bulk drug PLI incentives: Divi’s Laboratories’s its large-scale API and custom synthesis manufacturing, benefiting from PLI scheme incentives supporting domestic bulk drug production self-reliance.
Laurus Labs’s diversified API manufacturer benefiting from bulk drug PLI scheme incentives: Laurus Labs’s its diversified pharmaceutical manufacturing model, benefiting from PLI scheme incentives supporting domestic active pharmaceutical ingredient production.
Aarti Drugs’s API manufacturer benefiting from bulk drug self-reliance incentive scheme: Aarti Drugs’s its API manufacturing business, benefiting from India’s bulk drug self-reliance incentive scheme supporting reduced import dependence.
Sustained sector-wide demand: Broader structural demand growth across PLI scheme pharma and API manufacturing beneficiaries supports all three companies within this theme.

Company	CMP (Rs)	Growth Driver	Sector
Divi’s Laboratories	–	Large-scale api manufacturer benefiting from bulk drug pli incentives	Pli
Laurus Labs	–	Diversified api manufacturer benefiting from bulk drug pli scheme incentives	Pli
Aarti Drugs	–	Api manufacturer benefiting from bulk drug self-reliance incentive scheme	Pli

Divi’s Laboratories: Large-scale api manufacturer benefiting from bulk drug pli incentives

Divi’s Laboratories is among the PLI scheme beneficiary stocks in pharma and API manufacturing, its large-scale API and custom synthesis manufacturing, benefiting from PLI scheme incentives supporting domestic bulk drug production self-reliance.

Divi’s Laboratories’ scale positions it to capture meaningful PLI-linked incentive benefits as India reduces API import dependence.

Laurus Labs: Diversified api manufacturer benefiting from bulk drug pli scheme incentives

Laurus Labs is among the PLI scheme beneficiary stocks in pharma and API manufacturing, its diversified pharmaceutical manufacturing model, benefiting from PLI scheme incentives supporting domestic active pharmaceutical ingredient production.

Laurus Labs’ diversification across API, generics and CDMO services provides multiple avenues for capturing PLI-linked incentive benefits.

Get SEBI-Registered Research on PLI Pharma API Manufacturing Stocks

Aarti Drugs: Api manufacturer benefiting from bulk drug self-reliance incentive scheme

Aarti Drugs is among the PLI scheme beneficiary stocks in pharma and API manufacturing, its API manufacturing business, benefiting from India’s bulk drug self-reliance incentive scheme supporting reduced import dependence.

Aarti Drugs’ domestic API manufacturing focus positions it to capture incentive benefits tied to India’s pharmaceutical self-reliance policy.

Download the Univest iOS App or Univest Android App to track Divi’s Laboratories, Laurus Labs and Aarti Drugs live prices.

Factors Affecting the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing

Execution track record: For the PLI scheme beneficiary stocks in pharma and API manufacturing, execution against disclosed plans remains the key determinant of realised growth.
Sector-wide demand trends: Broader demand trends across PLI scheme pharma and API manufacturing beneficiaries affect all three companies collectively.
Competitive intensity: Rising competition within PLI scheme pharma and API manufacturing beneficiaries could pressure margins even amid volume growth.
Input cost and supply chain factors: Cost and supply chain dynamics affect profitability for companies within this theme.
Policy and regulatory support: Government policy support toward PLI scheme pharma and API manufacturing beneficiaries affects the sustainability of this growth theme.

Benefits of the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing

Structural growth theme exposure: The PLI scheme beneficiary stocks in pharma and API manufacturing provide exposure to a sustained, structural growth theme rather than a short-term cycle.
Diversified company selection: Spanning three companies, this list reduces single-stock concentration risk within the theme.
Established execution capability: These companies bring existing scale and expertise to capture growth within PLI scheme pharma and API manufacturing beneficiaries.
Policy-aligned positioning: These stocks align with broader government policy priorities supporting this sector.
Multiple growth vectors: Different business models across these three names offer diversified ways to capture the same broad theme.

Risks of the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing

Execution risk: These companies still need to execute disclosed plans successfully to realise growth.
Valuation considerations: Strong recent sector performance means current valuations may already reflect growth expectations for the PLI scheme beneficiary stocks in pharma and API manufacturing.
Competitive pressure: Rising competition within PLI scheme pharma and API manufacturing beneficiaries could affect market share and margins over time.
Cyclicality risk: Demand within PLI scheme pharma and API manufacturing beneficiaries could prove more cyclical than currently anticipated.
Broader market sentiment risk: Overall market conditions can affect these stocks regardless of company-specific fundamentals.

How to Evaluate the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing

Among the PLI scheme beneficiary stocks in pharma and API manufacturing, compare execution track record against disclosed growth and expansion plans.
For the PLI scheme beneficiary stocks in pharma and API manufacturing, assess competitive positioning within the broader PLI scheme pharma and API manufacturing beneficiaries sector.
Track quarterly results to confirm continued execution progress.
Consider valuation relative to growth visibility for each name.
Combine sector-theme analysis with standard fundamental research.

How to Invest in the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing

Use the Univest platform to track quarterly results and expansion progress for the PLI scheme beneficiary stocks in pharma and API manufacturing.
Open a demat and trading account with Univest for zero-brokerage execution.
Track quarterly results for Divi’s Laboratories, Laurus Labs and Aarti Drugs through the Univest app.
Consult a SEBI-registered advisor before allocating capital to this theme.
Review positions periodically as execution progress and sector trends evolve.

Conclusion

Divi’s Laboratories, Laurus Labs and Aarti Drugs represent the PLI scheme beneficiary stocks in pharma and API manufacturing, each capturing different aspects of India’s sustained PLI scheme pharma and API manufacturing beneficiaries growth story. Historically, this structural theme has offered diversified exposure across multiple companies, though execution risk and valuation considerations remain important factors. Consult a SEBI-registered advisor before making investment decisions.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs

3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?

Ans. Divi’s Laboratories, Laurus Labs and Aarti Drugs are the PLI scheme beneficiary stocks in pharma and API manufacturing.

What drives Divi’s Laboratories’s growth in this theme?

Ans. Divi’s Laboratories benefits from large-scale API manufacturer benefiting from bulk drug PLI incentives.

What drives Laurus Labs’s growth in this theme?

Ans. Laurus Labs benefits from diversified API manufacturer benefiting from bulk drug PLI scheme incentives.

What drives Aarti Drugs’s growth in this theme?

Ans. Aarti Drugs benefits from API manufacturer benefiting from bulk drug self-reliance incentive scheme.

Is this theme purely cyclical or structural?

Ans. The PLI scheme beneficiary stocks in pharma and API manufacturing represent a structural growth theme, though cyclicality risk remains a consideration.

What risks apply to the 3 PLI Scheme Beneficiary Stocks in Pharma and API Manufacturing?

Ans. Key risks include execution risk, valuation considerations, and competitive pressure within the sector.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.